Heron Therapeutics | HRTX - Operating Expenses


Heron Therapeutics reported $40.55M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
ALKERMES USD 326.44M 1.41B Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amarin USD 51.48M 113K Dec/2025
ANI Pharmaceuticals USD 217.93M 287.88M Dec/2025
Anika Therapeutics USD 29.97M 116.84M Dec/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
Eisai JPY 199.9B 16.22B Dec/2025
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
Merck USD 10.16B 558M Dec/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 193.68M 27.32M Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Surmodics USD -245.35M 363.49M Sep/2024
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Veracyte USD 116M 7.24M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025